1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Drs. Braun and Brandt contributed equally to this work.
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
You have full text access to this OnlineOpen article
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial†
Article first published online: 1 AUG 2003
DOI: 10.1002/art.11104
Copyright © 2003 by the American College of Rheumatology
Additional Information
How to Cite
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Golder, W., Gromnica-Ihle, E., Kellner, H., Schneider, M., Sörensen, H., Zeidler, H., Reddig, J. and Sieper, J. (2003), Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis & Rheumatism, 48: 2224–2233. doi: 10.1002/art.11104
- †
Schering-Plough had no role in the study design or in the collection, analysis, or interpretation of the data. Essex Pharma, Munich, Germany, provided the study drug.
Publication History
- Issue published online: 1 AUG 2003
- Article first published online: 1 AUG 2003
- Manuscript Accepted: 14 APR 2003
- Manuscript Received: 14 FEB 2003
Funded by
- Schering-Plough USA, Kenilworth, NJ
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases, Arthritis Research & Therapy, 2011, 13, 3, R105
- 2, , , , , , , , , Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy, Rheumatology International, 2011,
- 3, , , , , , , , Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases, Immunologic Research, 2011,
- 4, , , , , , , , , , , , , Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome, Rheumatology, 2011, 50, 9, 1690
- 5, , , , , , Systemic Therapy With Conventional and Novel Immunomodulatory Agents for Ocular Inflammatory Disease, Survey of Ophthalmology, 2011, 56, 6, 474
- 6, , Anti-TNF-α therapy with infliximab in spondyloarthritides, Expert Review of Clinical Immunology, 2010, 6, 1, 9
- 7, , , , Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-α blockade, Clinical Rheumatology, 2010, 29, 7, 763
- 8, Soluble and Tissue Biomarkers in Ankylosing Spondylitis, Best Practice & Research Clinical Rheumatology, 2010, 24, 5, 671
- 9, , , , , , The Use of Artrofoon in the Treatment of Ankylosing Spondyloarthritis, Bulletin of Experimental Biology and Medicine, 2010, 148, 3, 474
- 10, , , , , , , A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis, Rheumatology International, 2009, 30, 11, 1437
- 11, , A systematic medline analysis of therapeutic approaches in ankylosing spondylitis, Rheumatology International, 2009, 29, 10, 1123
- 12, , , , , , Abdominal Pain in a Patient With Ankylosing Spondylitis Under Treatment With Infliximab, JCR: Journal of Clinical Rheumatology, 2009, 15, 5, 244
- 13, , Emergence of Crohn's Disease During Treatment with the Anti-Tumor Necrosis Factor Agent Etanercept for Ankylosing Spondylitis: Possible Mechanisms of Action, Seminars in Arthritis and Rheumatism, 2009, 39, 3, 176
- 14
- 15, , , , , , , , , , , , Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab, Arthritis Care & Research, 2009, 61, 8Direct Link:
- 16, , Infectious complications of biological therapy, Current Opinion in Rheumatology, 2009, 21, 4, 397
- 17, , , , , , Infliximab for treating axial spondylarthropathy in everyday practice, Joint Bone Spine, 2009, 76, 1, 39
- 18, , , , , , Two Cases with Ankylosing Spondylitis Using Infliximab (case report), Japanese Journal of Clinical Immunology, 2009, 32, 1, 61
- 19, , , , , , , , , Ankylosierende Spondylitis in Mittel- und Osteuropa, Zeitschrift für Rheumatologie, 2008, 67, 6, 503
- 20, , , , , , Clinical observations programme in SpA: disease parameters, treatment options and practical management issues, Rheumatology International, 2008, 29, 3, 239
- 21, , , , , , , , , , , Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period, Arthritis Care & Research, 2008, 59, 9Direct Link:
- 22, , , , , , , , , , , , , , , , , , , , , , , Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment, Arthritis & Rheumatism, 2008, 58, 1Direct Link:
- 23
- 24, , , , , , , , , Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept, Arthritis & Rheumatism, 2008, 58, 5Direct Link:
- 25, , , , , , , , Safety and Clinical Responses in Ankylosing Spondylitis after Three Months of Etanercept Therapy, Journal of Korean Medical Science, 2008, 23, 5, 852
- 26, , , , , , , Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation, Rheumatology, 2008, 47, 9, 1358
- 27, , , , Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A “real life†retrospective study on 175 patients, Joint Bone Spine, 2008, 75, 6, 680
- 28, , , , , , The Burden of Ankylosing Spondylitis in Spain, Value in Health, 2008, 11, 3Direct Link:
- 29, , , , , , , The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study, Arthritis Care & Research, 2008, 59, 2Direct Link:
- 30, , , , , , , , , , TNFα blockade in human diseases: An overview of efficacy and safety, Clinical Immunology, 2008, 126, 1, 13
- 31, Adalimumab in the treatment of arthritis, Therapeutics and Clinical Risk Management, 2007, 3, 1, 133
- 32, , Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease, Inflammatory Bowel Diseases, 2007, 13, 11Direct Link:
- 33, , , , Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Expert Review of Pharmacoeconomics & Outcomes Research, 2007, 7, 2, 155
- 34, , , , , , , , Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents, Arthritis Care & Research, 2007, 57, 4Direct Link:
- 35, , Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease, Current Treatment Options in Gastroenterology, 2007, 10, 3, 178
- 36, , , New therapeutic approaches for spondyloarthritis, Current Opinion in Rheumatology, 2007, 19, 3, 259
- 37, , , , , , Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis, Rheumatology International, 2007, 27, 10, 935
- 38, , , , , Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ‘off’ episodes in patients with Parkinson's disease, Current Medical Research and Opinion, 2007, 23, 4, 741
- 39, , Tumor necrosis factor as a therapeutic target of rheumatologic disease, Expert Opinion on Therapeutic Targets, 2007, 11, 11, 1369
- 40, , Anti-TNF-α agents in the treatment of psoriatic arthritis, Expert Opinion on Biological Therapy, 2006, 6, 2, 99
- 41, , , , Anti-Tumour Necrosis Factor-?? Therapy for Rheumatoid and Other Inflammatory Arthropathies, Drugs & Aging, 2006, 23, 11, 855
- 42, Current Treatment for Psoriatic Arthritis and Other Spondyloarthritides, Rheumatic Disease Clinics of North America, 2006, 32, 11
- You have free access to this content43, , Extended indications for anti-tumor necrosis factor-α therapy, APLAR Journal of Rheumatology, 2006, 9, 2Direct Link:
- You have free access to this content44, , , Infliximab (Remicade®): from bench to clinical practice. A paradigm shift in rheumatology practice, APLAR Journal of Rheumatology, 2006, 9, 2Direct Link:
- 45, , , , , , , , , Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial, Arthritis Care & Research, 2006, 55, 4Direct Link:
- 46, Infliximab: a chimeric anti-TNF- monoclonal antibody for the treatment of ankylosing spondylitis and other spondyloarthritides, Therapy, 2006, 3, 2, 191
- 47, Infliximab: a chimeric anti-TNF-α monoclonal antibody for the treatment of ankylosing spondylitis and other spondyloarthritides, Therapy, 2006, 3, 2, 191
- 48, Newer Therapeutic Approaches: Spondyloarthritis and Uveitis, Rheumatic Disease Clinics of North America, 2006, 32, 1, 75
- 49, , , , , Paraparesis due to exacerbation of preexisting spinal pseudoarthrosis following infliximab therapy for advanced ankylosing spondylitis, The Spine Journal, 2006, 6, 3, 325
- 50, , , , , , , , Polymorphisms within the Tumor Necrosis Factor–α Promoter Region in Patients with HLA-B27–Associated Uveitis, Ophthalmology, 2006, 113, 4, 695
- 51, , , Spondylarthrite ankylosante et ostéoporose, La Revue de Médecine Interne, 2006, 27, 5, 392
- 52, , , , Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab, Clinical Rheumatology, 2006, 26, 5, 811
- 53, , , , , , , , Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: Results of a fifty-four–week study, Arthritis Care & Research, 2006, 55, 5Direct Link:
- 54, The clinical application of etanercept in Chinese patients with rheumatic diseases, Modern Rheumatology, 2006, 16, 4, 206
- 55, , , , The treatment of the rheumatological manifestations of the inflammatory bowel diseases, Rheumatology International, 2006, 26, 11, 953
- 56, , , Topical application of the tumour necrosis factor-α antibody infliximab improves healing of chronic wounds, International Wound Journal, 2006, 3, 3Direct Link:
- 57, , , Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis, Current Opinion in Internal Medicine, 2006, 5, 5, 530
- 58, , , Anti–tumor necrosis factor α blockade in the treatment of juvenile spondylarthropathy, Arthritis & Rheumatism, 2005, 52, 7Direct Link:
- 59, , , , , , , , Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment, Rheumatology International, 2005, 26, 1, 58
- 60, , , Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis, Rheumatology International, 2005, 26, 5, 473
- 61, Differentiating the efficacy of the tumor necrosis factor inhibitors, Seminars in Arthritis and Rheumatism, 2005, 34, 5, 7
- 62, , Diverse effects of infliximab and etanercept on T lymphocytes, Seminars in Arthritis and Rheumatism, 2005, 34, 5, 23
- 63, , , , , , , Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT), Arthritis & Rheumatism, 2005, 52, 2Direct Link:
- 64, , , , , , , , Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies, Arthritis & Rheumatism, 2005, 52, 12Direct Link:
- 65, , , , , Infectious complications of tumor necrosis factor-α antagonists, International Journal of Dermatology, 2005, 44, 6Direct Link:
- 66
- 67, , Infliximab for the treatment of ankylosing spondylitis, Expert Opinion on Biological Therapy, 2005, 5, 8, 1095
- 68, , Infliximab use in Crohn’s disease, Expert Opinion on Biological Therapy, 2005, 5, 4, 589
- 69, , Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies, Drugs & Aging, 2005, 22, 6, 451
- 70, , , , , , , , Severe pyogenic infections in patients taking infliximab, Joint Bone Spine, 2005, 72, 4, 330
- 71, , , , Tratamiento biológico de las enfermedades reumáticas, Medicine - Programa de Formación Médica Continuada Acreditado, 2005, 9, 28, 1830
- 72, , Anti-TNF-α therapy in ankylosing spondylitis, Expert Opinion on Pharmacotherapy, 2004, 5, 7, 1497
- 73, , , , , , , , , Anti-TNFα therapy in rheumatoid arthritis and autoimmunity, Rheumatology International, 2004, 26, 3, 209
- 74
- 75, Dispelling the myths about ankylosing spondylitis, Internal Medicine Journal, 2004, 34, 11Direct Link:
- 76, Management of extraintestinal manifestations and other complications of inflammatory bowel disease, Current Gastroenterology Reports, 2004, 6, 6, 506
- 77, Management Strategies for Osteoarthritis, Ankylosing Spondylitis, and Gouty Arthritis, JCR: Journal of Clinical Rheumatology, 2004, 10, Supplement, S18
- 78, , , , , , Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid Arthritis, The American Journal of Gastroenterology, 2004, 99, 12, 2385
- 79
- 80, , , , , , , Structure-Modifying Capacity of Anti-Tumour Necrosis Factor-?? Therapy in Ankylosing Spondylitis, Drugs, 2004, 64, 24, 2793
- 81, , , The implications of biologic therapy in ankylosing spondylitis: Comment on the articles by Brandt et al and Braun et al, Arthritis & Rheumatism, 2004, 50, 7Direct Link:
- 82, Recent Advances in the Treatment of Spondyloarthropathy, Journal of the Korean Medical Association, 2003, 46, 11, 972
- 83, , , , , , , , , , , , , , , , , , , , , Adverse effects of biologics: a network meta-analysis and Cochrane overview, The Cochrane Library,Direct Link: